XML 17 R9.htm IDEA: XBRL DOCUMENT

Insider Trading Arrangements

3 Months Ended

Mar. 31, 2026

Item 5. Other Information

The following table describes for the three months ended March 31, 2026 each trading arrangement under which the Company's officers, directors or director affiliated investment funds adopted, materially modified, or terminated any contracts, instructions, or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any non-Rule 10b5-1 trading arrangement.

       Name and Position

       Action

       Adoption/
Termination
Date

       Rule 10b5-1(1)

       Non-Rule
10b5-1(2)

       Total Shares of
Common Stock
to be Sold

       Expiration
Date

Robert Lechleider, Chief Medical Officer

Termination

March 26, 2026

X

110,000

December 31, 2026

Robert Lechleider, Chief Medical Officer

Adoption

March 26, 2026

X

110,000

December 31, 2026

Kinney Horn, Chief Business Officer

Adoption

March 30, 2026

X

132,853

January 15, 2027

Isaac Barchas, Director

Adoption

March 31, 2026

X

11,048

March 15, 2027

ABHMC II LLC, Investor (4)

Adoption

March 31, 2026

X

408,504

December 31, 2027

Arsenal Bridge Venture II-B LLC, Investor (5)

Adoption

March 31, 2026

X

1,050

December 31, 2027

(1)

Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.

(2)

"Non-Rule 10b5-1 trading arrangement" as defined in Item 408(c) of Regulation S-K under the Exchange Act.

(3)

Represents the modification, as described in Rule 10b5-1(c)(1)(iv) under the Exchange Act, of a written plan adopted on December 24, 2025 that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.

(4)

The Rule 10b5-1 trading plan was adopted by ABHMC II LLC, or ABHMC. The shares held by ABHMC II LLC were received following an in-kind distribution of the Company's common stock from Arsenal Bridge Venture II, LLC, or ABV II, in accordance with its operating agreement. ABHMC is the managing member of ABV II. Mr. Barchas, a member of the Company's Board of Directors, is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares held by ABHMC. Mr. Barchas disclaims beneficial ownership of the shares covered by the Rule 10b5-1 trading plan, except to the extent of his pecuniary interest, if any.

(5)

The Rule 10b5-1 trading plan was adopted by Arsenal Bridge Venture II-B LLC, or ABV II-B. Mr. Barchas, a member of the Company's Board of Directors, is a co-founder and holder of a power of attorney with the ability to exercise voting and investment power over the shares held by ABV II-B. Mr. Barchas disclaims beneficial ownership of the shares covered by the Rule 10b5-1 trading plan, except to the extent of his pecuniary interest, if any.

Robert Lechleider

Trading Arrangements, by Individual

Name

Robert Lechleider

Title

Chief Medical Officer

Rule 10b5-1 Arrangement Adopted

true

Adoption Date

March 26, 2026

Rule 10b5-1 Arrangement Terminated

true